| Returns | 1W : -15% , 1M : 50.4%,1Y : 147.9% |
| Peers & Returns | 1W | 1M | 1Y |
| JAGSONPAL PHARMACEUTICALS LTD | -15% | 50.4% | 147.9% |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 1.4% | 9.6% | 11.8% |
| DR REDDYS LABORATORIES LTD | 4.4% | -1.4% | 65.2% |
| DIVIS LABORATORIES LTD | 2.5% | 16.4% | 101% |
| CIPLA LTD | 0.7% | 0.5% | 54.4% |
| BIOCON LTD | 2.5% | 7.7% | 62.3% |
| AUROBINDO PHARMA LTD | 5.4% | 12.2% | 92.5% |
| LUPIN LTD | 1.2% | -7.1% | 13.1% |
| TORRENT PHARMACEUTICALS LTD | -2.1% | -1.2% | 48.3% |
| Ratio | Value |
|---|---|
|
P/E P/B P/S |
19.6
P/E Calculated based on EPS of 3
[ Mar2020 - Standalone Results ] 1.49
P/B Calculated based on Book Value of 39.39
[ Mar2020 - Standalone Results ] 1.06
P/S Calculated based on Revenues of 144.986 Cr
[ TTM - Standalone Results ] |
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
130% 47% 199% |
| Year | Debt/Equity ratio | |
|---|---|---|
|
Debt/Equity ratio analysis
For all non-Banking industries, Good = Ratio less than 0.4 Average = Ratio between 0.4 and 0.6 Bad = Ratio greater than 0.6 Worst is considered between Standalone & Consolidated |
Standalone | Consolidated |
|
2020 2019 2018 Avg_3yrs |
0.05 0.04 0.09 0.06 |
- - - - |
|
[Last Annual Data : Mar2020]
|
||
| Pledged Shares |
0 % |
|---|---|
| As on : Sep2020 | |
If less than 25% | Good |
| If between 25% and 50% | Neutral |
| If greater than 50% | Bad |
| Standalone | 1 Qtr Growth | 4 Qtr Growth |
|---|---|---|
|
Revenue Op Profit EBIDT Net Income |
78.04% 52.88% 60.44% 58.94% |
34.8% 77.74% 91.37% 97.39% |
| QtrlyTrend |
8
Quarterly Trend analysis
The growth rate score are assigned as under: If ratio's 1Q growth is +ve, then 1. If -ve, then -1. If ratio's 4Q growth is +ve, then 1.If -ve, then -1. Growth Score= Sum of all the above scores for Revenue, Operating Profit and Net Income. Interpretation Good = Growth Score >=4 Neutral = Growth Score between 0 and 4 Bad = Growth Score less than 0 |
|
| Latest Qtr: Sep2020 | ||
